Hepatic sinusoidal obstruction syndrome (SOS) reduces the effect of oxaliplatin in colorectal liver metastases.
Détails
ID Serval
serval:BIB_2E90AB8170AE
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Hepatic sinusoidal obstruction syndrome (SOS) reduces the effect of oxaliplatin in colorectal liver metastases.
Périodique
Histopathology
ISSN
1365-2559 (Electronic)
ISSN-L
0309-0167
Statut éditorial
Publié
Date de publication
2012
Volume
61
Numéro
2
Pages
314-318
Langue
anglais
Notes
Publication types: Journal Article Publication Status: ppublish. pdf type: short report
Résumé
AIMS: Oxaliplatin is an important chemotherapeutic agent used to reduce hepatic colorectal metastases, resulting in tumour reduction and permitting surgical resection. This treatment has significant side effects, as oxaliplatin can induce sinusoidal obstruction syndrome (SOS) in the non-tumour-bearing liver, resulting in increased morbidity. We hypothesized that SOS might impede hepatic perfusion, thereby interfering with the tumour environment and attenuate the response to the chemotherapy.
METHODS AND RESULTS: From the prospective database of the Maastricht University Medical Centre we collected 50 patients with hepatic colorectal carcinoma metastases. All patients received neo-adjuvant oxaliplatin followed by partial hepatectomy. Metastases and non-tumour-bearing liver were studied histopathologically. Thirty-two of 50 (64%) patients showed SOS lesions, classified as mild (26%) and moderate-severe (38%). The response to treatment, as expressed in the tumour regression grade (TRG), was grade 1 (10%); grade 2 (14%); grade 3 (28%); grade 4 (32%) and grade 5 (16%). Statistical analysis showed that a higher grade of SOS was associated with a higher grade of TRG (P = 0.016).
CONCLUSION: Developing SOS is associated with a lower tumour response to neo-adjuvant oxaliplatin treatment. Hepatic hypoperfusion due to sinusoidal obstruction syndrome might induce hepatic hypoxia, diminishing the response to chemotherapy.
METHODS AND RESULTS: From the prospective database of the Maastricht University Medical Centre we collected 50 patients with hepatic colorectal carcinoma metastases. All patients received neo-adjuvant oxaliplatin followed by partial hepatectomy. Metastases and non-tumour-bearing liver were studied histopathologically. Thirty-two of 50 (64%) patients showed SOS lesions, classified as mild (26%) and moderate-severe (38%). The response to treatment, as expressed in the tumour regression grade (TRG), was grade 1 (10%); grade 2 (14%); grade 3 (28%); grade 4 (32%) and grade 5 (16%). Statistical analysis showed that a higher grade of SOS was associated with a higher grade of TRG (P = 0.016).
CONCLUSION: Developing SOS is associated with a lower tumour response to neo-adjuvant oxaliplatin treatment. Hepatic hypoperfusion due to sinusoidal obstruction syndrome might induce hepatic hypoxia, diminishing the response to chemotherapy.
Mots-clé
Adult, Aged, Antineoplastic Agents/adverse effects, Colorectal Neoplasms/drug therapy, Combined Modality Therapy, Female, Hepatectomy, Hepatic Veno-Occlusive Disease/etiology, Hepatic Veno-Occlusive Disease/pathology, Humans, Liver Neoplasms/drug therapy, Liver Neoplasms/pathology, Male, Middle Aged, Neoadjuvant Therapy, Organoplatinum Compounds/adverse effects, Prospective Studies, Treatment Outcome
Pubmed
Web of science
Création de la notice
18/12/2013 18:22
Dernière modification de la notice
20/08/2019 13:13